This was the stock's second consecutive day of losses.

Despite a rocky Q1 start to 2025 with a 4.3% market drop, AbbVie managed to thrive amid economic unease and shifting investor ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

Citigroup has reiterated its neutral stance on AbbVie, nudging its price target down from $210 to $205, despite the company’s ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Neutral. Analyst ...

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock traded at ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation.

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53% ...

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.